source
- Beacon eye gene therapy hits mark in late-stage studyBeacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.
- Iambic Therapeutics launches next-gen Enchant AI model and inks R&D partnership with AbbVieIambic Therapeutics, a San Diego‑based biotech founded in 2019, announced the release of the next generation of its Enchant artificial‑intelligence model. The updated model is intended to enhance…